Ropes & Gray advised Novo Nordisk in an asset purchase and license agreement with Omeros Corporation for Omeros’ drug candidate zaltenibart, a potential best-in-class treatment for rare blood and kidney disorders, in a deal worth up to $2.1 billion. The transaction was announced on October 15 and is expected to close during the fourth quarter of 2025.
Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zalenibart in all indications. Omeros is eligible to receive $340 million in upfront and near-term milestone payments, up to a total of $2.1 billion including potential development and commercial milestones, plus tiered royalties on net sales.
The Ropes & Gray team was led by life sciences licensing partner Hannah England, mergers & acquisitions partner Matt Byron, IP transactions associate Jackie Malmed and mergers & acquisitions associates Matthew Stylianou and James Gould, and included business restructuring partner Cristi Schwarzman, tax partner David Saltzman and mergers & acquisitions partner Chris Comeau.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.